A Comparison Study of Capsule and Orally Disintegrating Tablet and to Determine the Effect of Food and Water on the Pharmacokinetics of LY2886721 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs LY 2886721 (Primary) ; LY 2886721 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.